Truvian Sciences is a technology company.
Truvian Sciences has raised $110.0M across 1 funding round.
Truvian Sciences has raised $110.0M in total across 1 funding round.
Truvian Sciences, now operating as Truvian Health, is a San Diego-based healthcare technology company founded in 2015 that develops an automated benchtop blood testing analyzer called TruVerus. This platform integrates clinical chemistry, immunoassay, and hematology testing in a single run using proprietary disposable discs and support packs with all necessary reagents, delivering lab-accurate results instantly via a secure mobile platform to make routine blood testing convenient, affordable, and actionable for consumers and practitioners.[1][2][3][5] It targets primary care settings, clinics, and point-of-care environments, solving the problem of slow, off-site lab testing by enabling on-site, comprehensive panels like the TruWellness Panel (covering common tests such as lipid panel, comprehensive metabolic panel, and complete blood count), with staged FDA clearances in pursuit.[3][5] The company has raised $207.1 million across four funding rounds, including a recent $74 million, reflecting strong growth momentum amid diagnostics innovation.[3]
Truvian was founded in late 2015 by experts in healthcare, diagnostics, and consumer technology, including co-founder and COO Dena Marrinucci, who previously co-founded Epic Sciences in 2008 as its Chief Scientific Officer, leading liquid biopsy development, diagnostic partnerships, assay work, and CLIA lab establishment for prostate cancer products.[1][2] Key leadership includes CEO and President Jeff Hawkins and board members like Kim P. Kamdar (co-founder and board member), Jay Srinivasan (CEO/board), Tina Nova (recent board appointee with diagnostics/biotech executive experience), and others such as Megh Gupta, Emily Brown, and Ashok Krishnamurthi.[1][3][4] The idea emerged from founders' domain expertise to disrupt blood testing's inefficiencies; early traction built through team expansion with top scientists, engineers, and leaders, plus significant funding and pursuits like FDA clearances, positioning it for commercialization.[1][2][3][5]
Truvian rides the point-of-care diagnostics trend, accelerated by pandemics highlighting delays in traditional lab testing, toward patient-centric healthcare with on-demand, decentralized results.[1][5] Timing aligns with rising demand for affordable routine screening amid chronic disease prevalence (e.g., diabetes, heart conditions via TruWellness panels), fueled by AI/integration advances and consumer tech expectations.[5] Market forces like regulatory support for FDA-cleared benchtop systems and biomanufacturing scalability favor it, similar to peers in precision diagnostics (e.g., Color Genomics, Virta Health).[4] Truvian influences the ecosystem by elevating standards for integrated, on-site testing, potentially reducing healthcare costs and improving access in primary care globally.[1][3]
Truvian is poised for commercialization as it advances staged FDA clearances for its TruVerus platform, expanding the test menu to capture routine blood testing's massive market.[3][5] Key trends like AI-driven diagnostics, telehealth integration, and value-based care will propel growth, with its $207M funding enabling scale amid peers like insitro and Resilience.[3][4] Influence may evolve from innovator to market leader if it achieves full clearances and partnerships, transforming blood testing from a bottleneck to an enabler—disrupting an industry long due for on-site revolution, much like its founders did with liquid biopsies.[1][5]
Truvian Sciences has raised $110.0M in total across 1 funding round.
Truvian Sciences's investors include 7wire Ventures.
Truvian Sciences has raised $110.0M across 1 funding round. Most recently, it raised $110.0M Series C in February 2021.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Feb 1, 2021 | $110.0M Series C | 7wire Ventures |